The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Kowa Seeks 5.6 Billion Yen in Add’l Damages from Towa over Livalo Generics
Kowa said on April 5 that it has filed a new lawsuit against Towa Pharmaceutical seeking compensation of over 5.6 billion yen for damages relating to generic versions of its hypercholesterolemia treatment Livalo OD Tablets (pitavastatin). In the suit filed…
To read the full story
Related Article
- Towa’s Win in Livalo Damage Suit Now Final and Binding
October 7, 2022
- Towa Prevails in IP High Court Ruling for Livalo Damage Suit, Kowa Mulls Next Step
September 22, 2022
- Kowa Appeals to Intellectual Property High Court in Livalo Damage Suit
April 8, 2022
- Towa Wins Livalo Damage Suit; Kowa to Appeal Ruling
March 25, 2022
- Towa Files Additional Request for Livalo Patent Invalidity in December 2020
April 16, 2021
- Kowa Sues Towa Again over Livalo Generics, Seeking Over 4.8 Billion Yen in Additional Damages for FY2017
April 7, 2020
- Kowa Sues Towa over Livalo Generics, Demands 4.5 Billion Yen in Additional Damages
April 3, 2019
- Kowa Sues Towa for Damages Caused by Livalo Generics
June 25, 2018
- Kowa Gets High Court Backing in Livalo Patent Suit
April 9, 2018
- Kowa Wins Livalo Patent Suit against Towa
October 13, 2017
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Kowa Releases Glaucoma Drug Gla-Alpha in Malaysia
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…